Evidence-based patient safety advisory: blood dyscrasias.
Rarely, patients with blood disorders may seek to undergo plastic surgery. Although plastic surgeons are not expected to diagnose or manage blood disorders, they should be able to recognize which patients are suitable for surgery and which should be referred to a hematologist before a procedure. This practice advisory provides an overview of the perioperative steps that should be completed to ensure appropriate care for patients with blood disorders.
Haeck
Phillip C
PC
Arlington Heights, Ill. From the American Society of Plastic Surgeons' Patient Safety Committee.
Swanson
Jennifer A
JA
Schechter
Loren S
LS
Hall-Findlay
Elizabeth J
EJ
McDevitt
Noel B
NB
Smotrich
Gary A
GA
Reisman
Neal R
NR
Glasberg
Scot Bradley
SB
D000556:Ambulatory Surgical Procedures; D019317:Evidence-Based Medicine; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D018579:Patient Selection; D019651:Plastic Surgery Procedures; D012449:Safety
Greenhalgh T. How to Read a Paper: The Basics of Evidence-Based Medicine. 3rd ed. Oxford: Blackwell Publishing; 2006.
Lang TA, Secic M. How to Report Statistics in Medicine. 2nd ed. Philadelphia: American College of Physicians; 2006.
Straus SE, Richardson WS, Glasziou P, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM. 3rd ed. Philadelphia: Elsevier Churchill Livingstone; 2005.
Evidence-Based Medicine Working Group. Users’ Guides to the Medical Literature: Essentials of Evidence-Based Clinical Practice. Chicago: American Medical Association; 2002.
Chee YL, Crawford JC, Watson H, Greaves M. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures: British Committee for Standards in Haematology. Br J Haematol. 2008;140:496–504.
Kocher O, Cirovic C, Malynn E, et al. Obstetric complications in patients with hereditary thrombophilia identified using the LCx microparticle enzyme immunoassay: A controlled study of 5,000 patients. Am J Clin Pathol. 2007;127:68–75.
Sottilotta G, Oriana V, Latella C, et al. Genetic prothrombotic risk factors in women with unexplained pregnancy loss. Thromb Res. 2006;117:681–684.
Jauniaux E, Farquharson RG, Christiansen O, Exalto N. Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage. Hum Reprod. 2006;21:2216–2222.
Shaw RJ, Rogers SN. Venous microvascular anastomotic failure due to prothrombin gene mutation. Plast Reconstr Surg. 2005;115:1451–1452.
Drews CD, Dilley AB, Lally C, Beckman MG, Evatt B. Screening questions to identify women with von Willebrand disease. J Am Med Womens Assoc. 2002;57:217–218.
Dilley A, Drews C, Miller C, et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol. 2001;97:630–636.
Kadir RA, Economides DL, Sabin C, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998;351:485–489.
Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: Systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess. 2006;10:1–110.
Petros S, Siegemund T, Stolzenburg J, Siegemund A, Engelmann L. Coagulation monitoring with thrombin generation test during endoscopic extraperitoneal radical prostatectomy for prostate cancer in a patient with severe haemophilia B. Haemophilia 2007;13:677–679.
Stammers AH, Dorion RP, Trowbridge C, et al. Coagulation management of a patient with factor V Leiden mutation, lupus anticoagulant, and activated protein C resistance: A case report. Perfusion 2005;20:115–120.
Pivalizza EG. Perioperative use of the Thrombelastograph in patients with inherited bleeding disorders. J Clin Anesth. 2003;15:366–370.
Krolick MA. Successful percutaneous coronary intervention in a patient with severe haemophilia A using bivalirudin as the sole procedural anticoagulant. Haemophilia 2005;11:415–417.
Gerling V, Lahpor JR, Buhre W. Peri-operative management of an adult patient with type 2N von Willebrand’s disease scheduled for coronary artery bypass graft. Anaesthesia 2007;62:405–408.
Rodriguez-Merchan EC, Wiedel JD, Wallny T, et al. Elective orthopaedic surgery for inhibitor patients. Haemophilia 2003;9:625–631.
Hay CR, Brown S, Collins P, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol. 2006;133:591–605.
Macksey LF, White B. Anesthetic management in a pediatric patient with Noonan syndrome, mastocytosis, and von Willebrand disease: A case report. AANA J. 2007;75:261–264.
Filho AM, dos Santos RS, Costa J, Puppin AA, de Rezende RA, Beltrão GC. Oral surgery with fibrin sealants in patients with bleeding disorders: A case report. J Contemp Dent Pract. 2006;7:106–112.
Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM; HAEMATE P Surgical Study Group. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: A prospective multicenter trial in elective surgery. J Thromb Haemost. 2007;5:1420–1430.
Saroute AN, Brandao CM, Guedes M, Cavalheiro Filho C, Pomerantzeff PM. Patient with von Willebrand disease undergoing mitral valve repair: A strategy for the control of the coagulopathy. Arq Bras Cardiol. 2007;88:e4–e6.
Kuwahara M, Yurugi S, Takeda M, Fukuda K, Yoshioka A. Hemophilia B diagnosed by hematoma at the columella base. Plast Reconstr Surg. 2006;117:1647–1648.
Michiels JJ, Berneman ZN, van der P, Schroyens W, Budde U, van Vliet HH. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). Blood Coagul Fibrinolysis 2004;15:323–330.
Thompson AR, Gill JC, Ewenstein B, Mueller-Velten G, Schwartz B; Humate-P Study Group. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P). Haemophilia 2004;10:42–51.
Franchini M, Rossetti G, Tagliaferri A, et al. Efficacy and safety of factor VIII/von Willebrand’s factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. Haematologica 2003;88:1279–1283.
Cermelj M, Negro F, Schijman E, Ferro AM, Acerenza M, Pollola J. Neurosurgical intervention in a haemophilic child with a subdural and intracerebral haematoma. Haemophilia 2004;10:405–407.
Knott PD, Khariwala SS, Minarchek J. Hemophilia B and free tissue transfer: Medical and surgical management. Ann Plast Surg. 2005;54:336–338.
Sennett MM, de Alarcon PA. Successful use of ReFacto continuous infusion in two paediatric patients with severe haemophilia A undergoing orthopaedic surgery. Haemophilia 2004;10:655–660.
Caldicott D, Bonnin R, Lloyd J, Day P. Splenectomy in severe haemophilia. ANZ J Surg. 2004;74:921–925.
Murugan SJ, Viswanathan S, Thomson J, Parsons JM, Richards M. Heart surgery in infants with hemophilia. Ann Thorac Surg. 2006;81:336–339.
Delgado AV, Sanders JC. A simple technique to reduce epistaxis and nasopharyngeal trauma during nasotracheal intubation in a child with factor IX deficiency having dental restoration. Anesth Analg. 2004 99:1056–1057.
Dimichele D, Negrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006;12:352–362.
Goudemand J, Tagariello G, Lopaciuk F. Cases of surgery in high-responder haemophilia patients. Haemophilia 2004;2(Suppl 2):46–49.
Slaoui M, Lambert T, Stieltjes N, Claeyssens S, Borel-Derlon A. Intestinal surgery with activated recombinant factor VII prophylaxis in patients with haemophilia A and high responding inhibitors: A report of five cases. Blood Coagul Fibrinolysis 2004;15:687–691.
Stine KC, Shrum D, Becton DL. Use of FEIBA for invasive or surgical procedures in patients with severe hemophilia A or B with inhibitors. J Pediatr Hematol Oncol. 2007;29:216–221.
Janic D, Brdar R, Kristic Z, et al. Successful concurrent triple surgery in an adolescent patient with haemophilia A and inhibitors treated with recombinant factor VIIa. Haemophilia 2007;13:214–216.
Pekcelen Y, Yavuz AS, Namli S, Gücükoglu A. Short-course use of recombinant factor VIIa in a haemophilia patient with inhibitor undergoing cataract surgeries. Blood Coagul Fibrinolysis 2005;16:445–446.
Shu T, Moore DK, Moore RG. Initial report of retroperitoneoscopic renal surgery in a patient with factor VIII deficiency (classic hemophilia). Urology 2004;63:175–176.
Stumpf UC, Eberhardt C, Kurth AA. Orthopaedic limb salvage with a mega prosthesis in a patient with haemophilia A and inhibitors: A case report. Haemophilia 2007;13:435–439.
Daitoku K, Fukuda I, Kitagawa R, Minakawa M, Suzuki Y, Fukui K. Aortic valve replacement in a patient with myelodysplastic syndrome and interstitial pneumonia. Circ J. 2007;71:1826–1828.
Felbinger TW, Posner M, Eltzschig H, Kodali BS. Laparoscopic splenectomy in a pregnant patient with immune thrombocytopenic purpura. Int J Obstet Anesth. 2007;16:281–283.
Martini MZ, Lopez JS Jr, Gendler J, da Fonseca EV, Soares HA, Franzi SA. Idiopathic thrombocytopenic purpura presenting as post-extraction hemorrhage. J Contemp Dent Pract. 2007;8:43–49.
Koscielny J, von Tempelhoff GF, Ziemer S, et al. A practical concept for preoperative management of patients with impaired primary hemostasis. Clin Appl Thromb Hemost. 2004;10:155–166.
Sadler JE, Budde U, Eikenboom J, et al. Update on the pathophysiology and classification of von Willebrand disease: A report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4:2103–2114.
Federici AB. Clinical diagnosis of von Willebrand disease. Haemophilia 2004;10(Suppl 4):169–176.
Favaloro EJ, Bonar R, Kershaw G, et al. Laboratory diagnosis of von Willebrand’s disorder: Quality and diagnostic improvements driven by peer review in a multilaboratory test process. Haemophilia 2004;10:232–242.
Israels S, Schwetz N, Boyar R, McNicol A. Bleeding disorders: Characterization, dental considerations and management. J Can Dent Assoc. 2006;72:827.
Castaman G, Lethagen S, Federici A, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): Results from the European Study MCMDM-1VWD. Blood 2008;111:3531–3539.
Nitu-Whalley IC, Griffioen A, Harrington C, Lee CA. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. Am J Hematol. 2001;66:280–284.
Rivard GE, Aledort L; Alphanate Surgical Investigators. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease. Haemophilia 2008;14:271–275.
Sakurai Y, Shima M, Imai Y, Omura S, Kirita T, Yoshioka A. Successful use of recombinant factor VIII devoid of von Willebrand factor during multiple teeth extractions in a patient with type 3 von Willebrand disease. Blood Coagul Fibrinolysis 2006;17:151–154.
Maddox JM, Anderson JA, Plews D, Ludlam CA. Management of acquired von Willebrand’s syndrome in a patient requiring major surgery. Haemophilia 2005;11:633–637.
Stieltjes N, Altisent C, Auerswald G, et al. Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: Clinical experience. Haemophilia 2004;10:452–458.
Celiker V, Basgul E, Karagoz A, Dal D. Anesthesia in a patient with nasopharyngeal angiofibroma and hemophilia A. J Cardiothorac Vasc Anesth. 2004;18:819.
Sarris I, Arafa A, Konaris L, Kadir RA. Topical use of tranexamic acid to control perioperative local bleeding in gynaecology patients with clotting disorders: Two cases. Haemophilia 2007;13:115–116.
Coetzee MJ. The use of topical crushed tranexamic acid tablets to control bleeding after dental surgery and from skin ulcers in haemophilia. Haemophilia 2007;13:443–444.
Rubinger M, Rivard GE, Teitel J, Walker H; Inhibitor Subcommittee of the Association of Hemophilia Clinic Directors of Canada. Suggestions for the management of factor VIII inhibitors. Haemophilia 2000;1(Suppl):52–59.
Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 1999;3(Suppl 3):25–32.
Pruthi RK, Mathew P, Valentino L, et al. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery: Results from an open-label, randomized, multicenter trial. Thromb Haemost. 2007;98:726–732.
Smith MP, Ludlam CA, Collins P, et al. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: Plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost. 2001;86:949–953.
Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi FA, Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost. 2001;86:954–958.
Redwine J, Bold RJ. Perioperative care of the patient with hemophilia undergoing urgent appendectomy. Arch Surg. 2007;142:894–897.
Moeller-Bertram T, Kuczkowski KM, Benumof JL. Uneventful epidural labor analgesia in a parturient with immune thrombocytopenic purpura and platelet count of 26,000/mm3 which was unknown preoperatively. J Clin Anesth. 2004;16:51–53.
Szczepanik AB, Sikorska A, Slomkowski M, Konopka L. The use of vinca alkaloids in preparation for splenectomy of corticosteroid refractory chronic immune thrombocytopenic purpura patients. Int J Lab Hematol. 2007;29:347–351.
Perera AS, Gagne DJ, Papasavas P, Geyer SJ, Caushaj PF. Intraoperative death due to thrombotic thrombocytopenic purpura (TTP)-related acute myocardial failure in a patient undergoing laparoscopic splenectomy. Surg Laparosc Endosc Percutan Tech. 2007;17:559–561.
Martinelli I, Battaglioli T, Bucciarelli P, Passamonti SM, Mannucci PM. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation 2004;110:566–570.
Salvati EA, la Valle AG, Westrich G, et al. The John Charnley Award: Heritable thrombophilia and development of thromboembolic disease after total hip arthroplasty. Clin Orthop Relat Res. 2005;441:40–55.
Ruggeri M, Rodeghiero F, Tosetto A, et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: A retrospective survey. Blood 2008;111:666–671.
de la Cruz L, Berenguer B, de la PR. Thromboembolism after face lift because of mutation of the prothrombin gene. Plast Reconstr Surg. 2005;116:682–683.
Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: Prospective cohort study. Lancet 2003;362:523–526.
Wu O, Robertson L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: A systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost. 2005;94:17–25.
Sharathkumar AA, Stanley JC. Management of a child with renal artery stenosis and homozygous factor V Leiden mutation. J Pediatr Surg. 2008;43:e17–e19.
Agaba AE, Charaklias N, Babu-Victor A, et al. Antiphospholipid syndrome: A series of surgical emergencies and the current evidence for its management. Ann R Coll Surg Engl. 2006;88:370–374.
Hosoi S, Adachi T, Hara T, et al. Pulmonary embolism after minor surgery in a patient with low-risk thrombocythemia. J Anesth. 2004;18:146.
Schneider S, Sakert T, Lucke J, McKeown P, Sharma A. Cardiopulmonary bypass for a coronary artery bypass graft patient with heterozygous protein C deficiency and protein S deficiency. Perfusion 2006;21:117–120.
Dornan RI. Acute postoperative biventricular failure associated with antiphospholipid antibody syndrome. Br J Anaesth. 2004;92:748–754.
Crow SS, Sullivan VV, Aysola A, et al. Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin. Ann Thorac Surg. 2007;83:1547–1549.
Rice L, Baker KR. Current management of the myeloproliferative disorders: A case-based review. Arch Pathol Lab Med. 2006;130:1151–1156.
Ahmed A, Shah KA. Peri-operative management of a patient with uncontrolled polycythemia vera for above knee amputation. J Pak Med Assoc. 2004;54:34–36.
Michiels JJ, van Vliet HH, Berneman Z, et al. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients with von Willebrand disease type 1, 2 and 3. Clin Appl Thromb Hemost. 2007;13:14–34.
Borel-Derlon A, Federici AB, Roussel-Robert V, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): A prospective study of 50 patients. J Thromb Haemost. 2007;5:1115–1124.
Federici AB, Castaman G, Franchini M, et al. Clinical use of Haemate P in inherited von Willebrand’s disease: A cohort study on 100 Italian patients. Haematologica 2007;92:944–951.
Shortt J, Dunkley S, Rickard K, Baker R, Street A. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures. Haemophilia 2007;13:144–148.
Gill JC, Ewenstein BM, Thompson A, Mueller-Velton G, Schwartz BA; Humate-P Study Group. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): Use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia 2003;9:688–965.
Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: Ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost. 2002;87:224–230.
Mannucci PM, Chediak J, Hanna W, et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: A prospective, multicenter study. Blood 2002;99:450–456.
Lubetsky A, Schulman S, Varon D, et al. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease. Thromb Haemost. 1999;81:229–233.
Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia 1998;3(Suppl 3):33–39.
Federici AB, Sacco R, Stabile F, Carpenedo P, Zingaro E, Mannucci PM. Optimising local therapy during oral surgery in patients with von Willebrand disease: Effective results from a retrospective analysis of 63 cases. Haemophilia 2000;6:71–77.
Astermark J, Rocino A, Von Depka M, et al. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia 2007;13:38–45.